News from regeneron pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 04, 2021, 00:59 ET FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma

Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in...

Feb 27, 2021, 18:25 ET Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

Single administration of novel antibody cocktail controlled patients' allergic response to cat allergen, preventing early asthma reactions for the...

Feb 26, 2021, 06:46 ET EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

EU member states can utilize the positive CHMP opinion when making national decisions about use of the antibody cocktail, prior to a potential future ...

Feb 25, 2021, 07:00 ET Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with...

Feb 22, 2021, 13:00 ET FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics...

Feb 12, 2021, 16:15 ET Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Leerink 10th Annual Global Healthcare Conference ...

Feb 12, 2021, 01:00 ET The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

Libtayo was superior in extending overall survival compared to chemotherapy even with a high crossover rate Data are the basis for multiple ongoing...

Feb 11, 2021, 17:04 ET U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation

Upholds decision by U.S. District Court to invalidate Amgen's patent claims directed to PCSK9 antibodies Regeneron Pharmaceuticals, Inc. (NASDAQ:...

Feb 11, 2021, 14:00 ET FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol

Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is...

Feb 09, 2021, 17:22 ET FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

Following Priority Review Libtayo receives full approval in locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCC...

Feb 05, 2021, 06:30 ET Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA® U.S. net sales increased 10% to...

Feb 01, 2021, 09:59 ET New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting

Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic...

Jan 27, 2021, 07:00 ET REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed...

Jan 26, 2021, 07:00 ET Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of...

Jan 19, 2021, 16:15 ET Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating...

Jan 12, 2021, 17:45 ET Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses

New agreement covers 1.25 million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. supply to over 1....

Dec 29, 2020, 16:30 ET Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical...

Dec 17, 2020, 17:00 ET New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data...

Dec 16, 2020, 07:00 ET Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January...

Dec 05, 2020, 17:00 ET Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial...

Nov 30, 2020, 07:00 ET Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presented...

Nov 30, 2020, 00:59 ET Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

Pivotal trial showed more than four times as many children achieved itch reduction and more than three times as many children achieved clear or...

Nov 21, 2020, 19:56 ET Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2 Authorized for...

Nov 16, 2020, 07:00 ET Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has been included on the highly selective Dow Jones Sustainability World Index ...

Nov 05, 2020, 06:30 ET Regeneron Reports Third Quarter 2020 Financial and Operating Results

Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA® U.S. net sales increased 11% to...